**Supplemental Table 1—Change in Glycemic Outcomes from Baseline to Completion Visit**

|  |  |  |  |
| --- | --- | --- | --- |
|   | **Baseline Visit** | **Completion Visit** | **p-value** |
| **HbA1c, % (mmol/mol)** | 5.9 ± 0.1(41 ± 1.3) | 5.8 ± 0.1(40 ± 1.2)  | 0.017 |
| **AG, mg/dL** | 117 ± 4.9 | 110 ± 3.6 | 0.018 |
| **SD, mg/dL** | 35.1 ± 2.8 | 33.3 ± 2.4 | 0.131 |
| **CV** | 28.8 ± 1.3 | 28.9 ± 1.2 | 0.694 |
| **% time >140 mg/dL** | 20.9 ± 3.2 | 17.4 ± 2.5 | 0.046 |
| **% time >180 mg/dL** | 10.5 ± 2.4 | 7.6 ± 1.6 | 0.063 |
| **% time >250 mg/dL** | 3.4 ± 1.2 | 1.8 ± 0.6 | 0.067 |
| **% time <70 mg/dL** | 8.6 ± 1.6 | 9.3 ± 1.2 | 0.105 |
| **% time <54 mg/dL** | 2.1 ± 0.6 | 1.8 ± 0.3 | 0.169 |

n= 53; data displayed as mean ± SEM

HbA1c, hemoglobin A1c; AG, average glucose; SD, standard deviation; CV, coefficient of variation

**Supplemental Table 2— Change in Glycemic Outcomes in Participants with an Interval CF Exacerbation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Baseline Visit****(n=11)** | **Exacerbation Visit****(n=12)** | **Completion Visit****(n=7)** | **p-value** |
| **HbA1c, % (mmol/mol)** | 6.4 ± 0.7(46.4 ± 6.9) | 6.4 ± 0.8(46.4 ± 6.8) | 6.1 ± 0.3(43.2 ± 3.0) | 0.266 |
| **AG, mg/dL** | 127 ± 13 | 130 ± 13 | 116 ± 5 | 0.090 |
| **SD, mg/dL** | 46.7 ± 8.5 | 43.2 ± 7.4 | 40.8 ± 4.5 | 0.175 |
| **CV** | 35.3 ± 2.9 | 31.6 ± 2.7 | 35.0 ± 3.0 | 0.134 |
| **% time >140 mg/dL** | 28.7 ± 7.0 | 29.2 ± 7.5 | 21.4 ± 4.0 | 0.015 |
| **% time >180 mg/dL** | 12.6 ± 2.5 | 30.6 ± 8.6 | 18.7 ± 3.9 | 0.491 |
| **% time >250 mg/dL** | 5.2 ± 3.6 | 5.3 ± 3.7 | 1.5 ± 0.9 | 0.554 |
| **% time <70 mg/dL** | 24.5 ± 3.0 | 25.2 ± 9.6 | 20.7 ± 2.9 | 0.202 |
| **% time <54 mg/dL** | 3.6 ± 1.6 | 1.1 ± 0.4 | 1.3 ± 0.6 | 0.215 |

n=12 total participants with at least two complete visits, one of which was an exacerbation visit

Data displayed as mean ± SE

HbA1c, hemoglobin A1c; AG, average glucose; SD, standard deviation; CV, coefficient of variation